Fig. 1

Elevated Expression of PRMT6 in Glioma and Its Association with Poor Prognosis. A-C: Analysis of PRMT6 mRNA expression in various grades and subtypes of glioma using data from TCGA and CGGA databases. D-E: Kaplan-Meier survival analysis showing overall and progression-free survival of glioma patients with high and low PRMT6 expression in the TCGA dataset. F: Kaplan-Meier survival analysis of overall survival in glioma patients with high and low PRMT6 expression in the CGGA dataset. G-I: Analysis of PRMT6 protein and mRNA expression in normal human brain glial cell line (HEB) and glioma cell lines (LN229, U118, U87, U251). J: Clinical sample collection and analysis of PRMT6 expression in different grades of glioma patients and normal brain tissue (NBT). K-L: Representative immunohistochemistry images of PRMT6 in different grades of glioma patients and NBT. Kruskal-Wallis test and Dunn’s multiple comparisons test were used. Scale bar = 100 μm